CEO and Other Selling Stockholders Register Resale of 8.27M Shares, Creating Significant Market Overhang

summarizeSummary

Tempest Therapeutics filed a final prospectus for the resale of 8.27 million shares by selling stockholders, including CEO Matthew Angel, representing over 57% of outstanding shares, with no proceeds going to the company.

check_boxKey Events

• Finalizes Resale Registration

  This 424B3 prospectus finalizes the registration for the resale of 8,268,495 shares of common stock by selling stockholders, following the S-3 filings on March 30 and April 2, 2026.

• Significant Share Overhang

  The shares registered for resale constitute approximately 57.65% of the company's currently outstanding common stock, creating a substantial potential supply of shares on the market.

• CEO Among Selling Stockholders

  Matthew Angel, the company's President and CEO, is listed as a selling stockholder, with 4,837,070 shares directly held and additional shares through Factor Bioscience Inc.

• No Proceeds to Company

  Tempest Therapeutics will not receive any proceeds from the sale of these shares, as it is a secondary offering by existing stockholders.

auto_awesomeAnalysis

This 424B3 filing finalizes the registration for the resale of a substantial block of shares by existing stockholders, including CEO Matthew Angel. The 8.27 million shares represent approximately 57.65% of the company's currently outstanding common stock, creating a significant overhang on the stock price. The company will not receive any proceeds from these sales, meaning this event provides no new capital to Tempest Therapeutics, which recently disclosed a "going concern" warning. While the shares were initially issued as consideration for an asset acquisition, the immediate availability for resale by key insiders, particularly the CEO, signals potential selling pressure and raises concerns about insider conviction, especially in light of the company's precarious financial position.